Provided by Tiger Fintech (Singapore) Pte. Ltd.

Perspective Therapeutics

3.92
+0.03000.77%
Post-market: 3.950.0300+0.77%19:55 EDT
Volume:410.95K
Turnover:1.59M
Market Cap:290.98M
PE:-3.23
High:3.94
Open:3.90
Low:3.79
Close:3.89
Loading ...

Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating

MT Newswires Live
·
13 May

Perspective Therapeutics Reports Q1 2025 Results and Updates

TIPRANKS
·
13 May

Press Release: Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Dow Jones
·
13 May

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $342.00K Beat $144.30K Estimate

Benzinga
·
13 May

Perspective Therapeutics Reports Q1 2025 Net Loss of $18.2M, EPS Unchanged at $0.25; R&D Expenses Surge by 92%

Reuters
·
13 May

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

GlobeNewswire
·
01 May

Perspective Therapeutics Treats First Patient in Phase 1/2a Trial for Solid Tumors

MT Newswires Live
·
29 Apr

Perspective Therapeutics announces first patient dosed with PSV359

TIPRANKS
·
29 Apr

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

GlobeNewswire
·
29 Apr

Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?

Zacks
·
23 Apr

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

GlobeNewswire
·
17 Apr

Optimistic Buy Rating for Perspective Therapeutics Amid Strategic Clinical Developments and Strong Financial Position

TIPRANKS
·
11 Apr

Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy

MT Newswires Live
·
11 Apr

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire
·
11 Apr

Truist Financial Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
09 Apr

Perspective Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
07 Apr

Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating

MT Newswires Live
·
07 Apr

U.S. RESEARCH ROUNDUP-Apple, Tesla, Walmart

Reuters
·
07 Apr

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround

Zacks
·
02 Apr

Perspective Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Mar